National Planning Corp reduced its position in shares of Astrazeneca PLC (NYSE:AZN) by 11.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,601 shares of the company’s stock after selling 1,926 shares during the period. National Planning Corp’s holdings in Astrazeneca PLC were worth $495,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Salem Investment Counselors Inc. acquired a new stake in Astrazeneca PLC during the first quarter worth $107,000. Meeder Asset Management Inc. acquired a new stake in Astrazeneca PLC during the second quarter worth $105,000. Tompkins Financial Corp increased its stake in Astrazeneca PLC by 67.0% in the first quarter. Tompkins Financial Corp now owns 3,545 shares of the company’s stock worth $100,000 after buying an additional 1,422 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after buying an additional 3,782 shares during the last quarter. Finally, CENTRAL TRUST Co increased its stake in Astrazeneca PLC by 2.1% in the first quarter. CENTRAL TRUST Co now owns 4,499 shares of the company’s stock worth $140,000 after buying an additional 91 shares during the last quarter. Institutional investors own 14.33% of the company’s stock.

Shares of Astrazeneca PLC (NYSE:AZN) opened at 29.08 on Friday. The firm’s 50 day moving average is $32.47 and its 200-day moving average is $31.40. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. The company has a market cap of $73.63 billion, a PE ratio of 19.08 and a beta of 0.74.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The firm had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business’s quarterly revenue was down 9.9% on a year-over-year basis. During the same quarter last year, the company posted $0.83 EPS. Equities analysts expect that Astrazeneca PLC will post $1.85 earnings per share for the current year.

The business also recently disclosed a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be given a dividend of $0.44 per share. This represents a dividend yield of 2.98%. The ex-dividend date is Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio (DPR) is currently 44.92%.

TRADEMARK VIOLATION WARNING: This story was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/08/13/national-planning-corp-has-495000-position-in-astrazeneca-plc-azn.html.

A number of equities research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday. Cowen and Company reiterated a “hold” rating and issued a $34.00 price target on shares of Astrazeneca PLC in a research report on Friday, July 28th. Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Pareto Securities upgraded shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $33.39.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.